1. Reduced binding activity of vaccine serum to omicron receptor-binding domain
- Author
-
Mingzhi Li, Shiqi Weng, Quansheng Wang, Zibing Yang, Xiaoling Wang, Yanjun Yin, Qiuxiang Zhou, Lirong Zhang, Feifei Tao, Yihan Li, Mengle Jia, Lingdi Yang, Xiu Xin, Hanguang Li, Lumei Kang, Yu Wang, Ting Wang, Sha Li, and Lingbao Kong
- Subjects
COVID-19 ,omicron ,spike protein ,RBD ,binding activity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in E. coli and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (P < 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (P = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant.
- Published
- 2022
- Full Text
- View/download PDF